INDP · Indaptus Therapeutics, Inc.
Indaptus Therapeutics Inc (INDP)
What's happening
- INDP is up 5.74% today, trading at $3.13. — Live quote
- Volume today (14,451) is well below its 3-month average of 679,540. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-4.51 actual vs. $-4.45 estimated (-1.4%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-08-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $267.9M | $20.1M | $2.9M | $5.9M | $7.4M |
| P/E | -21.36 | -1.32 | -0.18 | -0.35 | -0.48 |
| Price/Book | 23.56 | 16.11 | 0.63 | -3.52 | 2.65 |
| ROE | -110.27% | -1224.30% | -343.17% | 1006.70% | -550.89% |
| ROA | -104.60% | — | -231.07% | -246.31% | -285.01% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-20; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -24.1%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on INDP
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$1.8M | -$2.2M | -$2.6M | -$4.5M | -$4.6M | -$3.1M | -$4.1M | -$3.9M |
| Net income | -$1.8M | -$2.5M | -$3.0M | -$5.2M | -$4.5M | -$3.1M | -$4.0M | -$3.8M |
| EPS (diluted) | $-0.02 | $-0.23 | $-2.98 | $-9.09 | $-9.11 | $-9.04 | $-13.16 | $-0.45 |
| EPS (basic) | $-0.02 | $-0.23 | $-2.98 | $-9.09 | $-9.11 | $-9.04 | $-13.16 | $-0.45 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $12.0M | — | $9.3M | $6.8M | $6.8M | $5.4M | $7.3M | $8.2M |
| Total liabilities | $615.4K | — | $6.2M | — | — | — | $3.4M | $2.2M |
| Stockholders' equity | $11.4M | $1.2M | $3.2M | $4.6M | -$1.7M | $2.8M | $3.9M | $6.0M |
| Total current assets | — | $2.2M | $9.3M | $6.4M | $6.4M | $5.0M | $6.6M | $7.6M |
| Total current liabilities | — | $933.0K | $6.2M | $2.2M | $8.5M | $2.6M | $3.4M | $2.2M |
| Cash & equivalents | $7.6M | $1.5M | $8.5M | $5.8M | $6.2M | $3.9M | $5.8M | $7.4M |
| Marketable securities (current) | $4.0M | — | — | — | — | — | — | — |
| Other current assets | $27.8K | — | — | — | — | — | — | — |
| Property, plant & equipment | — | — | — | — | — | — | — | — |
| Intangible assets | — | — | — | — | — | — | — | — |
| Other non-current assets | — | — | — | $392.6K | $392.6K | $392.6K | $638.3K | $504.7K |
| Accounts payable | $508.9K | $557.4K | $544.1K | $707.4K | $618.5K | $1.3M | $870.2K | $555.9K |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $1.3M | $1.1M | $21.7K | $16.4K | $6.0K | $160.3K | $4.3K | $102.0K |
| Retained earnings | -$85.6M | -$83.8M | -$81.3M | -$73.2M | -$70.2M | -$65.0M | -$60.4M | -$56.3M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — | — | — | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.9M | -$7.0M | -$3.2M | -$2.6M | -$4.0M | -$5.0M | -$3.4M | -$2.5M |
| Investing cash flow | -$4.0M | — | — | — | — | — | — | — |
| Financing cash flow | $12.0M | — | $5.9M | $2.2M | $6.3M | $3.2M | $1.8M | $2.6M |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Share-based compensation | -$64.3K | $227.2K | $936.4K | $150.6K | $180.8K | $240.9K | $1.5M | $444.2K |
| Purchases of investments | $4.0M | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$19.8M | -$15.4M | -$16.4M | -$14.9M | -$7.7M |
| Net income | -$20.8M | -$15.0M | -$15.4M | -$14.3M | -$7.7M |
| EPS (diluted) | $-21.58 | $-44.96 | $-1.83 | $-1.73 | — |
| EPS (basic) | $-21.58 | $-44.96 | $-1.83 | $-1.73 | $-1.89 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $9.3M | $7.3M | $14.9M | $28.1M | $40.6M |
| Total liabilities | — | $3.4M | $2.8M | $3.4M | $4.7M |
| Stockholders' equity | $3.2M | $3.9M | $12.1M | $24.6M | $35.9M |
| Total current assets | $9.3M | $6.6M | $14.0M | $27.2M | $40.4M |
| Total current liabilities | $6.2M | $3.4M | $2.8M | $3.4M | $4.6M |
| Cash & equivalents | $8.5M | $5.8M | $13.4M | $9.6M | $39.1M |
| Property, plant & equipment | — | — | $735 | $2.0K | $3.8K |
| Other non-current assets | — | $638.3K | $754.7K | $738.3K | $16.5K |
| Accounts payable | $544.1K | $870.2K | $806.0K | $1.4M | $2.5M |
| Common stock & paid-in capital | $21.7K | $4.3K | $84.0K | $84.0K | $82.6K |
| Retained earnings | -$81.3M | -$60.4M | -$45.4M | -$30.0M | -$15.7M |
| Accumulated other comprehensive income (loss) | — | — | — | $96.4K | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$14.8M | -$12.3M | -$13.4M | -$13.1M | -$11.3M |
| Investing cash flow | — | — | $17.1M | -$16.4M | $447.7K |
| Financing cash flow | $17.5M | $4.7M | — | — | $48.3M |
| Free cash flow | — | — | — | — | -$11.3M |
| Capital expenditures | — | — | — | — | $3.9K |
| Share-based compensation | $1.4M | $2.3M | $3.0M | $3.0M | $1.5M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding INDP as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2024-11-25 to 2026-01-20
Recent transactions
- Most recent: Ben-Tzvi Avraham (Director) — Grant / award of 25,000 shares on 2026-01-20.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Ben-Tzvi Avraham | Director | Grant / award | 2026-01-20 | 25,000 |
| Sassi Nir | Chief Financial Officer | Grant / award | 2025-12-22 | 26,758 |
| Meckler Jeffrey A | Co-Chief Executive Officer | Grant / award | 2025-12-22 | 216,617 |
| Newman Michael James | CSO and Director | Grant / award | 2025-12-22 | 52,204 |
| Linscott Walt Addison | Chief Operating Officer | Grant / award | 2025-12-22 | 54,421 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-01-20 | Ben-Tzvi Avraham | Director | Grant / award | 25,000 | $0.00 |
| 2025-12-22 | Sassi Nir | Chief Financial Officer | Grant / award | 26,758 | $2.03 |
| 2025-12-22 | Meckler Jeffrey A | Co-Chief Executive Officer | Grant / award | 216,617 | $2.03 |
| 2025-12-22 | Newman Michael James | CSO and Director | Grant / award | 52,204 | $2.03 |
| 2025-12-22 | Linscott Walt Addison | Chief Operating Officer | Grant / award | 54,421 | $2.03 |
| 2025-07-27 | Meckler Jeffrey A | Chief Executive Officer | Grant / award | 6,068 | $8.30 |
| 2024-11-25 | Meckler Jeffrey A | CEO and Director | Grant / award | 42,553 | $1.18 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:06 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-20 | 8-K | 2026-10-16 | View on SEC.gov → |
| 2026-09-30 | 8-K | 2026-09-29 | View on SEC.gov → |
| 2026-09-10 | 8-K | 2026-09-08 | View on SEC.gov → |
| 2026-09-04 | 8-K | 2026-09-02 | View on SEC.gov → |
| 2026-09-01 | 8-K | 2026-08-28 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-10 | View on SEC.gov → |
| 2026-06-24 | 8-K | 2026-06-17 | View on SEC.gov → |
| 2026-06-05 | 8-K | 2026-06-01 | View on SEC.gov → |
| 2026-05-15 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-15 | 8-K | 2026-05-15 | View on SEC.gov → |
| 2026-04-23 | 8-K | 2026-04-22 | View on SEC.gov → |
Recent news
Headlines about INDP (Indaptus Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Ting Yang Reduces Indaptus Therapeutics Stake to 6.48% Following Share Sales and Private Placement
Kalkine Media · 2026-10-21 -
Netflix, Intuitive Surgical, Pegasystems And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
Benzinga · 2026-10-21 -
Indaptus Therapeutics Closes $24 Million Private Placement, Issues 20.3 Million Shares
Minichart · 2026-10-20 -
Indaptus Therapeutics completes $24 million private placement of common stock
Investing.com · 2026-10-20 -
Form 8K Indaptus Therapeutics Inc For: 20 October By Investing.com
Investing.com UK · 2026-10-20 -
Penske Automotive, OPKO Health, Ericsson And Other Big Stocks Moving Higher On Thursday
Benzinga · 2026-10-15 -
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in Sep. 2026
Seeking Alpha · 2026-10-02 -
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
Yahoo Finance · 2026-09-25
No headlines in this category right now — try “All”.